In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blaze Bioscience Inc.

www.blazebioscience.com

Latest From Blaze Bioscience Inc.

Biopharma Quarterly Dealmaking Statistics, Q3 2016

In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.

BioPharmaceutical Deals

Start-Up Quarterly Statistics, Q3 2016

A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.

StartUps and SMEs Financing

Deals Shaping the Medical Industry, September 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.

Deals BioPharmaceutical

Denali Builds Neurodegeneration Pipeline Through Discovery, Collaborations And Lots Of Cash

The amount of venture capital that Denali Therapeutics Inc. has raised and the number of collaborations it's negotiated in less than two years is pretty staggering for a startup biopharmaceutical company, not to mention a startup focused on the central nervous system and neurodegeneration.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Blaze Bioscience Inc.
  • Senior Management
  • Heather Franklin, Pres. & CEO
    Julia Novak, PhD, VP, Research
    Mila Lobanova, VP, Finance & Operations
    Dennis Miller, PhD, SVP, Dev.
  • Contact Info
  • Blaze Bioscience Inc.
    Phone: (206) 535-8144
    530 Fairview Avenue North
    Ste. 1400
    Seattle, WA 98109
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register